In HMPB/BLZ945/anti-SIRPα@ATRA@fibrin treatment, HMPB exerts CAT-like function, anti-SIRPα antibodies and BLZ945 promote macrophage polarization from M2- to M1-like phenotype by blocking the corresponding CD47-SIRPα and CSF-1/CSF-1R signal axes combined with ATRA-induced differentiation of cancer stem cells, which restores the phagocytosis and killing ability of macrophages to tumor cells, effectively inhibiting postoperative recurrence of hepatocellular carcinoma (HCC). The gene discussed is SIRPA; the disease is neoplasm.